Risultati per: Studio chiarisce come l’Alzheimer si diffonde nel cervello

Insorge la stampa popolare dei tabloid: ‘Perché solo ai ricchi?’

In a highly publicized study from Sweden, sensitivity and specificity were both about 90%.

Tecnologia dell’Università Carlo Bo esplora uso di globuli rossi

The US Food and Drug Administration (FDA) recently approved donanemab, a monoclonal antibody to treat Alzheimer disease in its early stages. Marketed by Eli Lilly as Kisunla, the drug is the second to receive the FDA’s go-ahead for slowing Alzheimer disease, after lecanemab. Like lecanemab, donanemab is designed to clear amyloid plaque in people with mild cognitive impairment or mild dementia.

Modificate geneticamente abbattono i tassi di recidività

Focus sulla prevenzione delle malattie neurodegenerative

This cohort study investigates the association of changes in levels of plasma tau phosphorylated at threonine 181 and neurofilament light chain protein with psychotic symptoms in Alzheimer disease.

Un nuovo studio suggerisce che il primo farmaco Glp-1 impiegato per combattere diabete e obesità, può ridurre la perdita di massa cerebrale

Lo conferma uno studio su 1.200 persone

This Medical News article is an interview with retired neurologist Daniel Gibbs, who is living with Alzheimer disease.

Corteccia cerebrale più sottile e permeabilità dell’intestino

Dieta equilibrata e attività fisica possono prevenire malattie

Apre nuove prospettive contro l’osteoporosi

Almost all people who inherited 2 identical copies of the APOE4 gene variant had abnormally high levels of amyloid in their cerebrospinal fluid and brain by age 65 years, according to a new study that combined data from more than 3200 brain donors and about 10 000 participants with clinical data.

New England Journal of Medicine, Ahead of Print.